Emirates Health Services has announced the introduction of BYANNLI, an extended‑interval antipsychotic developed by Johnson & Johnson, for patients with schizophrenia at Al Amal Hospital for Mental Health. The move makes Al Amal the first government hospital in the United Arab Emirates to adopt this long‑acting therapy, which is administered as a single dose every six months, officials said.
The rollout aims to improve continuity of care and reduce relapse risk for people with chronic psychiatric disorders. Emirates Health Services executives described the decision as part of a broader effort to expand evidence‑based treatment options within public mental health services in the UAE.
BYANNLI introduced at Al Amal Hospital
Emirates Health Services announced that Al Amal Hospital will offer BYANNLI as an option for eligible patients, following regulatory approvals and clinical protocols, according to the agency. The treatment’s twice‑yearly dosing schedule marks a departure from daily oral medications and more frequent injections, officials noted.
Dr. Essam Al Zarouni, Executive Director of Medical Services at Emirates Health Services, said the adoption reflects the authority’s commitment to providing internationally approved therapies and strengthening the UAE’s position among countries prioritizing modern mental health care. Dr. Noor Al Mehairi, Director of Mental Health, emphasized that the new option targets one of the major barriers in psychiatric care: maintaining long‑term adherence.
Why long‑acting injectable therapies matter for schizophrenia treatment
Long‑acting injectable medications are increasingly recognised in clinical practice for their role in improving treatment adherence and reducing relapse. BYANNLI, as a twice‑yearly long‑acting injectable, potentially reduces the need for frequent dosing and simplifies follow‑up schedules, sources said.
Continuity of treatment is crucial in schizophrenia management because inconsistent adherence is strongly associated with symptom recurrence, hospital readmission and functional decline. Therefore, long‑acting injectable therapies are often considered when sustained symptom control and social stability are priorities for patients and caregivers.
Evidence, hospital performance and expected benefits
Al Amal Hospital has reported strong outcomes from existing long‑acting injectable programs, with figures cited by Emirates Health Services indicating readmission rates below 1% and adherence rates near 93% among patients on such treatments. The hospital also reported measurable symptom improvement in approximately 93% of patients receiving long‑acting therapies, underscoring the local clinical experience that informed the decision to introduce BYANNLI.
Officials say BYANNLI is intended to complement existing treatment pathways by offering a longer dosing interval, which may further boost adherence, reduce relapse risk and ease the burden on patients, families and clinical teams. Furthermore, the reduced frequency of administration could allow more efficient allocation of clinic time and resources, improving capacity for follow‑up and community‑based care.
Implementation considerations and care model integration
Emirates Health Services noted that introducing BYANNLI is part of a wider strategy to develop integrated, patient‑centred models of mental health care. Implementation will include clinical eligibility assessments, staff training, storage and administration protocols, and structured follow‑up plans to monitor efficacy and side effects, the authority said.
While long‑acting injectables can support adherence, clinicians emphasise the need for continued psychosocial support, family engagement and routine monitoring. Healthcare teams typically balance pharmacological advances with rehabilitation, psychotherapy and social interventions to support recovery and quality of life.
Safety monitoring and patient selection
As with any antipsychotic, appropriate patient selection and ongoing safety monitoring are essential. Officials recommend that prescribers follow approved guidelines and informed‑consent processes, assess potential contraindications, and schedule regular clinical reviews to evaluate therapeutic response and tolerability.
Policy alignment and wider implications for mental health services in the UAE
Authorities framed the BYANNLI rollout as consistent with national priorities on family wellbeing and the UAE’s Quality of Life 2031 agenda, which seeks to improve healthcare outcomes and support community resilience. The initiative aligns with efforts to expand accessible, high‑quality mental health services across public facilities.
Observers said the public sector introduction of an extended‑interval injectable could influence private providers and clinical guidelines, prompting wider availability and shared protocols. Emirates Health Services will likely monitor real‑world outcomes and resource impacts to inform potential broader adoption across the country.
Meanwhile, the move may reduce treatment gaps for patients who face logistical barriers to frequent dosing, including transportation challenges or competing caregiving responsibilities. For caregivers, less frequent clinic visits can translate into reduced disruption and improved family stability.
What to watch next
Going forward, Emirates Health Services plans to track clinical and operational metrics related to BYANNLI use, including adherence, relapse rates, hospital readmissions and patient‑reported outcomes. Updates on any expanded rollouts or protocol refinements are expected as data accumulate and clinicians share experience across sites.
Stakeholders and clinicians should watch for published outcome data and official guidance on eligibility and monitoring. The initial introduction at Al Amal Hospital will serve as an early case study for integration of long‑acting antipsychotic options into government mental health services.
In conclusion, the addition of BYANNLI to Al Amal Hospital’s formulary represents a measured step toward enhancing continuity of care for people with schizophrenia in the UAE. Officials said the next steps will focus on careful implementation, outcome monitoring and potential scaling across public mental health facilities in support of long‑term stability and improved quality of life for patients and families.
